Title:
BISPECIFIC ANTIBODY TO HUMAN TIM-3 AND HUMAN CD39, AND APPLICATIONS THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/195532
Kind Code:
A1
Abstract:
The present invention addresses the problem of producing an antibody or an antibody derivative having a more highly effective immune checkpoint inhibitory effect. More specifically, the present invention addresses the problem of producing an antibody or an antibody derivative having a more highly effective immune checkpoint inhibitory effect, having the action of strengthening immune activity against cancer cells, and having a cancer treatment effect. The present invention has demonstrated that the abovementioned problem can be solved by providing a heterodimer-type antibody or antibody derivative that has the property of binding to the TIM-3 antigen and the property of binding to the CD39 antigen. More specifically, the present invention provides a heterodimer-type antibody or antibody derivative having the property of binding to the TIM-3 antigen, having the property of binding to the CD39 antigen, and having the action of strengthening immune activity against cancer cells.
Inventors:
NAKAMURA NORIHIRO (JP)
NAKAJIMA KANTO (JP)
MISHIMA YUJI (JP)
MATSUMOTO NORIKO (JP)
NAKAJIMA KANTO (JP)
MISHIMA YUJI (JP)
MATSUMOTO NORIKO (JP)
Application Number:
PCT/JP2023/014336
Publication Date:
October 12, 2023
Filing Date:
April 07, 2023
Export Citation:
Assignee:
BRIGHTPATH BIOTHERAPEUTICS CO LTD (JP)
International Classes:
A61K39/395; C07K16/46; A61P35/00; A61P35/02; A61P37/04; C07K16/28; C12Q1/06; G01N33/574; C12N15/13; C12P21/08
Foreign References:
| JP2021527138A | 2021-10-11 |
Other References:
MISHIMA YUJI, NAKAJIMA KANTO, SHIRAISHI MAMORU, MATSUMURA HARUKA, ARAMAKI TAKAHIKO, MATSUMOTO NORIKO, NAKAMURA NORIHIRO: "235 Novel biparatopic TIM-3 antibody effectively blocks multiple inherent ligands and activates anti-tumor immunity", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 9, no. Suppl 2, 12 November 2021 (2021-11-12), pages A251 - A251, XP093097991, DOI: 10.1136/jitc-2021-SITC2021.235
MATSUMOTO NORIKO, MISHIMA YUJI, NAKAJIMA KANTO, ARAMAKI TAKAHIKO, SHIRAISHI MAMORU, MATSUMURA HARUKA, NAKAMURA NORIHIRO: "1364 Bispecific antibodies that block TIM-3 and CD39 induce anti-tumor efficacy and immune response by blocking multiple suppressive mechanisms", J IMMUNOTHER CANCER, 10 November 2022 (2022-11-10), pages A1413 - A1413, XP093097993, DOI: 10.1136/jitc-2022-SITC2022.1364
SHAHBAZI MEHDI, MOULANA ZAHRA, SEPIDARKISH MAHDI, BAGHERZADEH MOJGAN, REZANEJAD MARYAM, MIRZAKHANI MOHAMMAD, JAFARI MOHAMMAD, MOHA: "Pronounce expression of Tim-3 and CD39 but not PD1 defines CD8 T cells in critical Covid-19 patients", MICROBIAL PATHOGENESIS, ACADEMIC PRESS LIMITED, NEW YORK, NY., US, vol. 153, 1 April 2021 (2021-04-01), US , pages 104779, XP093097995, ISSN: 0882-4010, DOI: 10.1016/j.micpath.2021.104779
WEIMER PAULINE, WELLBROCK JASMIN, STURMHEIT TABEA, OLIVEIRA-FERRER LETICIA, DING YI, MENZEL STEPHAN, WITT MARIUS, HELL LOUISA, SCH: "Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by γδ T Cells in Ovarian Cancer", CELLS, vol. 11, no. 6, pages 964, XP093097997, DOI: 10.3390/cells11060964
BRAUNECK FRANZISKA, WEIMER PAULINE, SCHULZE ZUR WIESCH JULIAN, WEISEL KATJA, LEYPOLDT LISA, VOHWINKEL GABI, FRITZSCHE BRITTA, BOKE: "Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma", FRONTIERS IN MEDICINE, vol. 8, XP055915322, DOI: 10.3389/fmed.2021.763773
MATSUMOTO NORIKO, MISHIMA YUJI, NAKAJIMA KANTO, ARAMAKI TAKAHIKO, SHIRAISHI MAMORU, MATSUMURA HARUKA, NAKAMURA NORIHIRO: "1364 Bispecific antibodies that block TIM-3 and CD39 induce anti-tumor efficacy and immune response by blocking multiple suppressive mechanisms", J IMMUNOTHER CANCER, 10 November 2022 (2022-11-10), pages A1413 - A1413, XP093097993, DOI: 10.1136/jitc-2022-SITC2022.1364
SHAHBAZI MEHDI, MOULANA ZAHRA, SEPIDARKISH MAHDI, BAGHERZADEH MOJGAN, REZANEJAD MARYAM, MIRZAKHANI MOHAMMAD, JAFARI MOHAMMAD, MOHA: "Pronounce expression of Tim-3 and CD39 but not PD1 defines CD8 T cells in critical Covid-19 patients", MICROBIAL PATHOGENESIS, ACADEMIC PRESS LIMITED, NEW YORK, NY., US, vol. 153, 1 April 2021 (2021-04-01), US , pages 104779, XP093097995, ISSN: 0882-4010, DOI: 10.1016/j.micpath.2021.104779
WEIMER PAULINE, WELLBROCK JASMIN, STURMHEIT TABEA, OLIVEIRA-FERRER LETICIA, DING YI, MENZEL STEPHAN, WITT MARIUS, HELL LOUISA, SCH: "Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by γδ T Cells in Ovarian Cancer", CELLS, vol. 11, no. 6, pages 964, XP093097997, DOI: 10.3390/cells11060964
BRAUNECK FRANZISKA, WEIMER PAULINE, SCHULZE ZUR WIESCH JULIAN, WEISEL KATJA, LEYPOLDT LISA, VOHWINKEL GABI, FRITZSCHE BRITTA, BOKE: "Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma", FRONTIERS IN MEDICINE, vol. 8, XP055915322, DOI: 10.3389/fmed.2021.763773
Attorney, Agent or Firm:
UCHIYAMA Tsutomu et al. (JP)
Download PDF: